Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
IPO Year: 2021
Exchange: NASDAQ
Website: acumenpharm.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/26/2024 | $7.00 | Buy | Citigroup |
| 12/12/2023 | $8.00 | Buy | Deutsche Bank |
| 7/20/2023 | $9.00 → $14.00 | Buy | BofA Securities |
| 5/18/2023 | $13.00 | Overweight | Cantor Fitzgerald |
| 7/15/2022 | $15.00 | Buy | BTIG Research |
| 6/30/2022 | $15.00 | Buy | H.C. Wainwright |
| 1/21/2022 | $16.00 → $14.00 | Neutral → Buy | B of A Securities |
| 7/26/2021 | $27.00 | Buy | UBS |
| 7/26/2021 | $27.00 | Buy | Stifel |
| 7/26/2021 | $20.00 | Neutral | BofA Securities |
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
3 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)
Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st
CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today the appointment of James Doherty, Ph.D., as President and Chief Development Officer, effective February 1, 2024, reporting to Daniel O'Connell, Chief Executive Officer. Dr. Doherty's responsibilities will include oversight of clinical and non-clinical development, chemistry, manufacturing & controls and regulatory functions. "We are extremely excited to welcome Jim, who brings extensive experience and demonstrat
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced Derrell Porter, M.D., has joined its Board of Directors. "We are thrilled to welcome Dr. Porter to our Board of Directors at a time when we're rapidly advancing clinical development of ACU193," said Daniel O'Connell, President and Chief Executive Officer of Acumen Pharmaceuticals. "Dr. Porter brings significant expertise in drug development and commercialization to the Board as we develop a novel and p
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer's Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer's disease (AD) Sabirnetug demonstrated selective, dose-dependent target engagement of amyloid beta oligomers (AβOs), statistically significant amyloid plaque reduction within higher dose cohorts, and low overall levels of ARIA-E Phase 2 ALTITUDE-AD clinical trial of sabirnetug is ongoing with enrollment completion expected 1H 2025 NEWTON, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic solub
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that target
Expect ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, to complete enrollment in the first half of 2025Expect to announce topline results of Phase 1 study to support subcutaneous administration of sabirnetug in the first quarter of 2025Cash, cash equivalents and marketable securities of $258.9 million as of Sept. 30, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceut
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, Nov. 13, 2024, at 1:15 p.m. PT (4:15 p.m. ET). The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic
NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register
Late-breaking presentation highlights the pTau217 assay as an effective and efficient tool to screen participants for ALTITUDE-AD that reduces unnecessary amyloid PET scans and lumbar puncture procedures for those who are not eligible NEWTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today presented updated data on a validated research-use plasma pTau217 assay to screen potential participants in the ongoing Phase 2 ALTITUDE-AD clinical trial of sabirnetug, at the 17th Annual Cl
- Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer's disease - Late-breaking presentation to be held Thursday, Oct. 31, at 9:30 a.m. CET NEWTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that it will present a late-breaking presentation featuring insights from its participant screening approach used in the ongoing Phase 2 ALTITUDE-AD clinical trial evaluating
Drapkin brings decades of biotech and pharma experience as the company prepares for clinical trial development. Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson's and Alzheimer's, today announced the appointment of Kim Drapkin as Board Chair. She will help guide the strategic direction of LucyTx as the company enters its next phase of growth: clinical trial development. "It's an honor to lead LucyTx's Board. The company's non-traditional approach to developing treatments for complex diseases is already paying off, and I'm eager to contribute to both their clinical and st
NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Bank of America CNS Therapeutics Virtual Conference on Monday, Oct. 7, 2024, at 8:00 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days. About Acumen Pharmaceuticals, Inc. Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxi
144 - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
10-Q - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
8-K - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
EFFECT - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
ARS - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
DEFA14A - Acumen Pharmaceuticals, Inc. (0001576885) (Filer)
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13D/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G/A - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
SC 13G - Acumen Pharmaceuticals, Inc. (0001576885) (Subject)
Citigroup initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $7.00
Deutsche Bank initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $8.00
BofA Securities resumed coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $14.00 from $9.00 previously
Cantor Fitzgerald initiated coverage of Acumen Pharmaceuticals with a rating of Overweight and set a new price target of $13.00
BTIG Research initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $15.00
H.C. Wainwright initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $15.00
B of A Securities upgraded Acumen Pharmaceuticals from Neutral to Buy and set a new price target of $14.00 from $16.00 previously
UBS initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $27.00
Stifel initiated coverage of Acumen Pharmaceuticals with a rating of Buy and set a new price target of $27.00
BofA Securities initiated coverage of Acumen Pharmaceuticals with a rating of Neutral and set a new price target of $20.00
Expect ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, to complete enrollment in the first half of 2025Expect to announce topline results of Phase 1 study to support subcutaneous administration of sabirnetug in the first quarter of 2025Cash, cash equivalents and marketable securities of $258.9 million as of Sept. 30, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceut
NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register
NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the Company will host a virtual R&D Day on Wednesday, Oct. 2 at 10:00 a.m. ET. The webcast will highlight Acumen's strategic vision, and focus on the mechanistic rationale, pre-clinical and clinical data that support further development of sabirnetug as a treatment for early AD. Featured Speakers Acumen management and scientific leadership will be joined by external key opi
Actively enrolling subjects in ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease Dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024 with topline results anticipated in the first quarter of 2025 Cash, cash equivalents and marketable securities of $281.4 million as of Jun. 30, 2024, expected to support current clinical and operational activities into the first half of 2027 Company to host conference call and webcast today at 8:00 a.m. ET NEWTON, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-sta
NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report second quarter 2024 financial results on Tuesday, August 13, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register a
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va., May 14, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeuti
CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register a
CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN.
CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter financial results on Monday, Nov. 13, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease, today announced that the Company will report second quarter financial results on Tuesday, August 8, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including